Skip to content

HEMolyse and Organ damage imPROvement in sickle cell disease by VoxElotor. An open-label one stage phase II design.HEMOPROVE

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-513096-41-00
Acronym
APHP200750
Enrollment
35
Registered
2024-08-12
Start date
2022-03-24
Completion date
2024-12-04
Last updated
2024-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sickle cell disease

Brief summary

Improvement of Intravascular hemolysis, as defined by a ≥20% decrease of plasma Hemoglobin (µmol/l) between W0 and W48 weeks

Detailed description

Evolution between W0 and W48 weeks in intravascular hemolysis, as measured by absolute and relative (%) changes from baseline in plasma Hemoglobin (µmol/l) and free plasma Heme (µmol/l), Measurement of total hemoglobin mass based on the CO rebreathing technique (g of Hb / kg), or a stable evolution (i.e. decrease ≤ 10%) in patients initially under EPO therapy and who decreased or discontinued EPO during the study period., RBC lifespan by measurement of alveolar CO (in days), Blood volumes by CO rebreathing method (Total Mass of Hemoglobin (g of Hb), Total blood volume (L), RBC mass (g), Plasma Volume (L) ), Blood viscosity, Cerebral perfusion measured by MRI, Cerebral vaso-reactivity measured by transcranial Doppler (Breath holding test) and Near Infra Red Spectroscopy, Cognitive performance measured by MoCA, Improvement in the 6 minutes walk test on : Time spent under Sp02 88 and 90%, Borg Rating of Perceived Exertion (RPE), distance., Renal perfusion and amount of deoxyhemoglobin by MRI and Iron deposits in renal cortex by MRI, Glomerular Filtration Rate measurements, urine concentration capacity (fasting urinary osmolarity), urine albumin/creatinine ratio, Concomitant treatment observation: decrease / interruption of EPO dose, Safety;(VOC, ACS, Priapism) presence/absence of each signs, RBC properties: density, hemoglobin affinity , viscosity, deformability, senescence parameters, HbF/cell measure, Blood lactate concentration during stress test (submaximal cardiopulmonary exercise test) and echocardiography during submaximal cardiopulmonary exercise test, at rest, ∼2 mmol.L-1 (LT1), ∼4 mmol.L-1 and during the recovery phase to evaluate parameters of left ventricular (LV) contractility, cardiac output and diastolic function

Interventions

DRUGOxbryta 500 mg film-coated tablets

Sponsors

Assistance Publique Hopitaux De Paris
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Improvement of Intravascular hemolysis, as defined by a ≥20% decrease of plasma Hemoglobin (µmol/l) between W0 and W48 weeks

Secondary

MeasureTime frame
Evolution between W0 and W48 weeks in intravascular hemolysis, as measured by absolute and relative (%) changes from baseline in plasma Hemoglobin (µmol/l) and free plasma Heme (µmol/l), Measurement of total hemoglobin mass based on the CO rebreathing technique (g of Hb / kg), or a stable evolution (i.e. decrease ≤ 10%) in patients initially under EPO therapy and who decreased or discontinued EPO during the study period., RBC lifespan by measurement of alveolar CO (in days), Blood volumes by CO rebreathing method (Total Mass of Hemoglobin (g of Hb), Total blood volume (L), RBC mass (g), Plasma Volume (L) ), Blood viscosity, Cerebral perfusion measured by MRI, Cerebral vaso-reactivity measured by transcranial Doppler (Breath holding test) and Near Infra Red Spectroscopy, Cognitive performance measured by MoCA, Improvement in the 6 minutes walk test on : Time spent under Sp02 88 and 90%, Borg Rating of Perceived Exertion (RPE), distance., Renal perfusion and amount of deoxyhemoglobin by

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026